In June 2026, Globe Life executive Rebecca E. Zorn exercised 2,000 stock options and sold 2,000 common shares at prices between US$169.70 and US$170.41. Analysts maintain a positive outlook on the insurer, highlighting an expected 6.3% sales growth rate for 2026 and a favorable Zacks Rank #2. Despite a recent quarter that missed EPS and book value per share estimates, Globe Life has been repeatedly cited as a top sales-growth name, underscoring confidence in its underlying business momentum. The company's narrative projects US$6.8 billion in revenue and US$1.3 billion in earnings by 2028, requiring 5.1% yearly revenue growth. Investors should also weigh ongoing DOJ and SEC investigations that could materially affect the company.
Globe Life IncInsider selling and mixed earnings miss vs. positive sales growth outlook and analyst rating create conflicting signals.